Trials / Completed
CompletedNCT05615467
A Study of Effect of LY3556050 on Metformin in Healthy Participants
An Open-Label Study in Healthy Participants to Evaluate the Effect of LY3556050 on Metformin Pharmacokinetics
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate how much Metformin gets into the bloodstream and how long the body takes to get rid of it when it is administered orally in combination with LY3556050 in healthy participants. Iohexol will be administered to evaluate kidney function. Each enrolled participant will remain in the study for up to 7 weeks including the screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3556050 | Administered orally. |
| DRUG | Metformin | Administered orally. |
| DRUG | Iohexol | Administered IV. |
Timeline
- Start date
- 2022-11-15
- Primary completion
- 2022-12-27
- Completion
- 2022-12-27
- First posted
- 2022-11-14
- Last updated
- 2023-01-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05615467. Inclusion in this directory is not an endorsement.